Oritavancin: Mechanism of Action

Management of multidrug-resistant enterococcal infections

(2011) C.A. Arias et al.   CLINICAL MICROBIOLOGY AND INFECTION

Comparison of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Canada: results of the CANWARD 2007–2009 study

(2011) Kimberly A. Nichol et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-Resistant Enterococci To Effect Rapid Bacterial Killing

(2010) A. Belley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New Lipoglycopeptides

(2010) George G. Zhanel et al.   DRUGS

In vitro activity of oritavancin against community-associated meticillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA)

(2010) Louis D. Saravolatz et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Oritavancin Population Pharmacokinetics in Healthy Subjects and Patients with Complicated Skin and Skin Structure Infections or Bacteremia

(2009) C. M. Rubino et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates

(2009) F. F. Arhin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization

(2009) Oscar Domenech et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium

(2009) G. A. McKay et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin

(2009) F. F. Arhin et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Vancomycin and Oritavancin Have Different Modes of Action in Enterococcus faecium

(2009) Gary J. Patti et al.   JOURNAL OF MOLECULAR BIOLOGY

Oritavancin Binds to Isolated Protoplast Membranes but not Intact Protoplasts of Staphylococcus aureus

(2009) Sung Joon Kim et al.   JOURNAL OF MOLECULAR BIOLOGY

Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

(2008) M. Rybak et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Effect of Polysorbate 80 on Oritavancin Binding to Plastic Surfaces: Implications for Susceptibility Testing

(2008) F. F. Arhin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ultrastructural Effects of Oritavancin on Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus

(2008) A. Belley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureus Cells In Vitro

(2008) A. Belley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis

(2008) S. Lemaire et al.   CLINICAL MICROBIOLOGY AND INFECTION

Oritavancin Exhibits Dual Mode of Action to Inhibit Cell-Wall Biosynthesis in Staphylococcus aureus

(2008) Sung Joon Kim et al.   JOURNAL OF MOLECULAR BIOLOGY